Clinical Trials Logo

Severe Depression clinical trials

View clinical trials related to Severe Depression.

Filter by:

NCT ID: NCT06112652 Recruiting - Clinical trials for Major Depressive Disorder

Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique

Start date: December 4, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to explore the effectiveness and safety of different doses of neural regulation under the guidance of pBFS technology in improving symptoms in patients with moderate to severe depressive disorders.

NCT ID: NCT05964036 Recruiting - Depression Clinical Trials

pBFS-guided High-dose TMS Over DMPFC for Treatment-resistant Major Depressive Disorder

Start date: July 21, 2023
Phase: N/A
Study type: Interventional

The investigators aim to evaluate the safety and efficacy of pBFS-guided DMPFC target and high-dose rTMS therapy for the treatment of patients with treatment-resistant depression

NCT ID: NCT05957341 Not yet recruiting - Clinical trials for Major Depressive Disorder

pBFS Guided 20min Inter-session Interval rTMS Treatment for MDD

Start date: July 30, 2023
Phase: N/A
Study type: Interventional

The investigators aim to explore the efficacy and safety of rTMS therapies with different intervals between sessions for treating patients with moderate to severe depression.

NCT ID: NCT05842278 Recruiting - Clinical trials for Major Depressive Disorder

The Dosage Effect of pBFS Guided rTMS Treatment for MDD

Start date: July 7, 2023
Phase: N/A
Study type: Interventional

The investigators aim to find the optimal dosage of the pBFS-guided rTMS treatment for patients with moderate to severe depression.

NCT ID: NCT04618250 Completed - Schizophrenia Clinical Trials

Improving Physical Health in Patients With Psychiatric Disorders in General Practice (SOFIA)

SOFIA
Start date: November 6, 2020
Phase: N/A
Study type: Interventional

People with a severe mental illness (SMI) have an increased risk for premature mortality, predominantly due somatic health conditions. Evidence indicates that prevention and improved treatment of somatic conditions in patients with SMI could reduce this excess mortality. This paper reports a protocol designed to evaluate the feasibility and acceptability of a coordinated co-produced care programme (SOFIA model) in the general practice setting to reduce mortality and improve quality of life in patients with severe mental illness. The primary outcomes are description of study feasibility (recruitment and retention) and acceptability. The SOFIA trial is designed as cluster randomized controlled trial targeting general practices in two regions in Denmark. 12 practices will each recruit 15 community-dwelling patients aged 18 and older with severe mental illness (SMI). Practices will be randomized in a ratio 2:1 to deliver a coordinated care program or care-as-usual during a 6 month period. An online randomized algorithm is used to perform randomization. The coordinated care program comprises enhanced educational training of general practitioners and their clinical staff, and prolonged consultations focusing on individual needs and preferences of the patient with SMI. Assessments are administered at baseline, and at end of study period. If delivery of the intervention in the general practice setting proves feasible, a future definitive trial to determine the effectiveness of the intervention in reducing mortality and improving quality of life in patients with SMI can take place.

NCT ID: NCT03922425 Enrolling by invitation - Schizophrenia Clinical Trials

Community-based Mental Health Care for People With Severe and Enduring Mental III Health

RECOVER-E
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

A single-blinded hybrid effectiveness-implementation trial (Type II), that both evaluates the intervention outcomes (clinical and service use outcomes) through patient-randomization in the implementation sites, as well as evaluates the implementation strategy chosen for the intervention and its impact on implementation outcomes (e.g. adoption, fidelity, acceptability and maintenance (continued implementation) of the intervention).

NCT ID: NCT03892473 Active, not recruiting - Schizophrenia Clinical Trials

Community-based Mental Health Care for People With Severe and Enduring Mental III Health ( RECOVER-E )

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

A single-blinded hybrid effectiveness-implementation trial (Type II), that both evaluates the intervention outcomes (clinical and service use outcomes) through patient-randomization in the implementation sites, as well as evaluates the implementation strategy chosen for the intervention and its impact on implementation outcomes (e.g. adoption, fidelity, acceptability and maintenance (continued implementation) of the intervention).

NCT ID: NCT03862209 Recruiting - Schizophrenia Clinical Trials

Community-based Mental Health Care for People With Severe and Enduring Mental Ill Health (RECOVER-E) Croatia

RECOVER-E
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

To contribute to improving the level of functioning and quality of life and mental health outcomes for people with severe and enduring mental ill health (SMI) (schizophrenia, bipolar disorder, depression) by adapting and up scaling the implementation of a community‐based service delivery model in Croatia.

NCT ID: NCT03837340 Active, not recruiting - Schizophrenia Clinical Trials

Community-based Mental Health Care for People With Severe and Enduring Mental Ill Health

RECOVER-E
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

A single-blinded hybrid effectiveness-implementation trial (Type II), that both evaluates the intervention outcomes (clinical and service use outcomes) through patient-randomization in the implementation sites, as well as evaluates the implementation strategy chosen for the intervention and its impact on implementation outcomes (e.g. adoption, fidelity, acceptability and maintenance (continued implementation) of the intervention).

NCT ID: NCT03380442 Not yet recruiting - Severe Depression Clinical Trials

Psilocybin and Depression

Psilo101
Start date: September 2018
Phase: Phase 2
Study type: Interventional

The main aim of the study is to investigate the possible long-term therapeutic effects of psilocybin on the symptoms of severe depression, as well as the brain mechanisms underlying these changes. Depression severity is assessed before and after (i.e., 1 week, 3 months and 6 months after) a single dose of psilocybin and compared to respective scores of a group receiving an active placebo, ketamine. Brain activity (using functional magnetic resonance imaging) is measured before and one week after drug administration in order to determine whether changes in brain networks related to emotional and self-referential processing correlate with any observed changes in depression scores. Further, blood samples will be obtained from the participants and analyzed in order to reveal gene expression and molecular level correlates underlying rapid antidepressant effects, and to identify biomarkers that predict treatment outcome.